Institute of Biology, Pharmaceutical Chemistry and Biotechnology (IBMCB)
Legal representative: Dr. V. Gregoriou
Scientific coordinator: Dr. A. Pintzas
SCIENTIFIC PROFILE AND SPECIALISATION OF THE COORDINATING INSTITUTION
The IBMCB/ NHRF Coordinating Institution has the scientific and administrative capacity to coordinate ACCC. NHRF researchers and services have successfully completed dozens of pre-clinical and clinical research projects on cancer with major scientific publications in collaboration with the participating institutions.
Scientific fields: Molecular resistance agents, cancer biomarkers, imaging, bioinformatics data analysis, drug development and transfer, clinical and preclinical animal and cell models.
A. Chemical Carcinogenesis Group (Dr. V. Souliotis, Dr. P. Georgiadis, M. Bekyrou, regular members).
This group focuses on molecular mechanisms of cell response to DNA damage (DDR) and on Epigenetics in the prevention of cancer.
B. Molecular Endocrinology Group (Dr. M. Alexis, Dr. D. Mitsiou, regular members).
This group focuses on Molecular Physiology and Pharmacology of Steroid Hormone Receptors.
Dr. M. Alexis has more than 70 publications in international peer-reviewed journals.
C. Signal Mediated Gene Expression Group (Dr. A. Pintzas, V. Kosmidou, regular members).
This group focuses on the conversation of oncogenic and apoptotic pathways for use in therapy.
Dr. A. Pintzas has more than 60 publications in peer-reviewed journals.
D. Bioinformatics Group (Dr. A. Hatziioannou, Dr. O. Papadodima, regular members).
The group focuses on synergy of molecular networks using semantic, functional information.
Dr. A. Hatziioannou has more than 130 publications in international journals.
E. The Biomedical Applications Unit (Dr. V. Zoumpourlis, N. Youroukos regular members).
The group focuses on stem cell applications in therapy, drug toxicity control.
Dr. V. Zoumpourlis has more than 70 publications in international journals.
F. The Laboratory of Dr. V. Gregoriou in NHRF participates in the development of new systems for the chemical imaging of neoplasms and the transfer of anti-cancer drugs based on new nanomaterials.
Dr. V. Gregoriou has more than 70 publications in international peer-reviewed journals.